Lastly, as new treatment approaches continue to be explored in MM, we also discuss novel cereblon E3 ligase modulator (CELMoDTM) agents including iberdomide (CC-220) and mezigdomide (CC-92480). This evidence concerns the gene CRBN and Miyoshi myopathy.